Industry Insights - The Ministry of Industry and Information Technology issued the "Action Plan for the Integration of Industrial Internet and Artificial Intelligence," aiming to enhance the integration of AI in the industrial sector, with a target of upgrading at least 50,000 enterprises by 2028 [2][6] - The brain-computer interface company Strong Brain Technology recently completed approximately 2 billion yuan in financing, marking the second-largest financing in the brain-computer interface sector after Neuralink [6] - The National Medical Products Administration is optimizing the review and approval process for urgently needed foreign drugs to meet clinical demands, encouraging simultaneous global R&D and applications in China [6] Market Developments - The copper market is expected to see an upward trend in 2026, with domestic copper prices exceeding 100,000 yuan/ton by the end of 2025, driven by supply-demand improvements and intense long-term contract negotiations [4][7] - Starlink has connected over 9 million active users across seven continents, indicating a growing market for satellite internet services [7] Company Updates - Lenovo announced a collaboration with NVIDIA to establish an "AI Cloud Super Factory," with the latest NVIDIA technology being a key component of this partnership [9] - ByteDance's TikTok Shop reached 400 million active consumers in 2025, with a GMV nearing 100 billion USD, ranking fifth among global e-commerce platforms [10] - Alphabet's market capitalization reached 3.89 trillion USD, surpassing Apple's 3.85 trillion USD, highlighting divergent AI strategies between the two companies [10]

Core Viewpoint - Company Ayhuilong (688575.SH) is entering the rapidly growing brain-computer interface (BCI) sector through a strategic partnership with Shenzhen Brain Machine Starlink Technology Co., Ltd, which has raised concerns from the stock exchange regarding the feasibility and details of this collaboration [1][2][3] Group 1: Partnership Details - Ayhuilong signed a strategic cooperation framework agreement with Brain Machine Starlink to integrate BCI technology with clinical and market resources for product development and market expansion [1][2] - Brain Machine Starlink, established in September 2025 with a registered capital of 5 million yuan, focuses on comprehensive diagnosis, treatment, and rehabilitation of brain diseases, with several products still in early development stages [3][4] - Ayhuilong holds a 4% indirect stake in Brain Machine Starlink, which is currently developing non-invasive technology products, distinguishing it from Neuralink's invasive approach [4] Group 2: Exchange Inquiries - The Shanghai Stock Exchange issued a rapid inquiry to Ayhuilong, requesting detailed disclosures on the commercial viability of Brain Machine Starlink, the feasibility of collaborative R&D, and the potential for future investments [2][5][6] - The first inquiry focuses on the commercial rationale of Brain Machine Starlink, including its technology routes, product types, and development status, as well as the timeline for future agreements and revenue sharing [4][5] - The second inquiry addresses the feasibility of collaborative R&D, asking for details on ongoing projects, expected investments, and the timeline for signing specific agreements [5][6] - The third inquiry concerns the feasibility of future investments, requesting specifics on potential equity investments or funding support for Brain Machine Starlink [6] Group 3: Financial Performance - Ayhuilong's core business involves the development, production, and sales of in vitro diagnostic instruments and related reagents, with a significant market presence in hospitals [7] - The company experienced a dramatic increase in revenue and net profit in 2022, attributed to sales growth in both non-COVID and COVID-related products, but has since faced a decline in performance [8] - From 2023 to 2025, Ayhuilong's revenue and net profit have shown consecutive declines, with a reported net profit of 60.42 million yuan in the first three quarters of 2025, down 72.36% year-on-year [8][9] - As of September 2025, Ayhuilong's cash flow has significantly decreased, with a net cash flow of 64.99 million yuan, and total receivables and inventory amounting to 1.171 billion yuan [9][10]

经济观察网1月7日，上交所连开两张"罚单"，分别对科创板公司亚辉龙、英集芯及有关责任人予以监管 警示，原因为相关公司在披露涉及"脑机接口"业务信息时存在不准确、不完整的情形。 ...

1月6日收盘后，亚辉龙披露《关于自愿披露签署战略合作框架协议的公告》称，公司与脑机星链签订《战略合作框架协议》，双方将在产品研发、市场 推广以及股权投资等方面开展合作。 亚辉龙公告称，脑机星链是一家以人工智能为核心驱动力，深耕非侵入式与侵入式双技术路径的企业，已开发脑电采集分析仪等产品。 1月7日，亚辉龙及有关责任人、英集芯及有关责任人，均被上交所予以监管警示。 | 证券代码 | 证券简称 | 监管类型 | 处理事由 | 涉及对象 | 处理日期 | | --- | --- | --- | --- | --- | --- | | 688575 | 亚辉龙 | 监管警示 | 关于深圳市亚辉龙生物科技股份有 | 上市公司,董秘 | 2026-01-07 | | | | | 限公司的决定书 | | | | 688209 | 英集芯 | 监管警示 | 关于深圳英集芯科技股份有限公司 | 上市公司,董秘 | 2026-01-07 | | | | | 的决定书 | | | 综合来看，亚辉龙、英集芯近期在发布的公告或互动平台上，提及与"脑机接口"等热点概念相关信息，但存在信息披露不准确、不完整，风险提示不充 分等问题。 监管 ...

1月7日，上交所连开两张"罚单"，分别对科创板公司亚辉龙、英集芯及有关责任人予以监管警示，原因为相关公司在披露涉及"脑机接口"业务信息时存 在不准确、不完整的情形。 | 证券代码 | 证券简称 | 监管类型 | 外理事由 | 涉及对象 | 外理日期 | | --- | --- | --- | --- | --- | --- | | 688575 | 亚辉龙 | 监管警示 | 关于深圳市亚辉龙生物科技股份有 | 上市公司,董秘 | 2026-01-07 | | | | | 限公司的决定书 | | | | 688209 | 英集示 | 监管警示 | 关于深圳英集芯科技股份有限公司 | 上市公司,董秘 | 2026-01-07 | | | | | 的地完书 | | | 亚辉龙1月6日股价上涨6.52%、成交量较前一个交易日增长299%。当天收盘后，该公司自愿披露与深圳脑机星链科技有限公司签订《战略合作框架协 议》，称双方将在产品研发、市场推广以及股权投资等方面开展合作，并披露后者为"深耕非侵入式与侵入式双技术路径的领先企业"。该公告披露后引 发市场关注，上交所火速下发问询函，要求公司说明合作具体情况。在监管督促下， ...

1月7日，上交所连开两张"罚单"，分别对科创板公司亚辉龙、英集芯及有关责任人予以监管警示，原因为相关公司在披露涉及"脑 机接口"业务信息时存在不准确、不完整的情形。 | 证券代码 | 证券简称 | 监管类型 | 外理事由 | 涉及对象 | 处理日期 | | --- | --- | --- | --- | --- | --- | | 688575 | 亚辉龙 | 监管警示 | 关于深圳市亚辉龙生物科技股份有 | 上市公司,董秘 | 2026-01-07 | | | | | 限公司的决定书 | | | | 688209 | 英集芯 | 监管警示 | 关于深圳英集芯科技股份有限公司 | 上市公司,董秘 | 2026-01-07 | | | | | 的决定书 | | | 亚辉龙1月6日晚自愿披露与脑机接口相关公司的框架协议，当晚收到上交所问询函，要求其进一步核实情况。另一家科创板公司英集芯也在1月 6日通过投资者互动平台透露关于脑机接口芯片领域的早期投资布局，因内容语焉不详，易引起误导，被上交所下发监管工作函。当前，两家公 司均已补充披露公告说明业务风险。 近期，"脑机接口"成为市场热点，多家公司股价连续涨停，引发监 ...

Group 1 - The Shanghai Stock Exchange issued a regulatory warning to YHLO (688575) and its then Secretary of the Board, Wang Mingyang, due to discrepancies in the company's disclosures regarding a strategic cooperation framework agreement with Shenzhen Brain Machine Starlink Technology Co., Ltd. [1] - YHLO announced a strategic cooperation with Brain Machine Starlink, focusing on product development, market promotion, and equity investment, highlighting the company's engagement in artificial intelligence and non-invasive/invasive technology paths [1][2] - Following media attention, YHLO issued a supplementary announcement clarifying that Brain Machine Starlink's current research products are based solely on non-invasive technology, with some products still in early development or preclinical stages [1][2] Group 2 - The "brain-computer interface" is currently a hot market concept, attracting significant investor interest, which led to a 6.52% increase in YHLO's stock price and a 299% rise in trading volume on the day of the announcement [2] - The Shanghai Stock Exchange emphasized the need for YHLO to ensure that disclosures regarding the cooperation with Brain Machine Starlink are accurate, complete, and not misleading, particularly given the inconsistencies in the statements about the invasive technology path [2] - The exchange noted that YHLO's announcements failed to adequately address key investor concerns regarding the feasibility and uncertainties of the collaboration, leading to the regulatory warning [2]

Core Viewpoint - The Shanghai Stock Exchange issued a regulatory warning to Shenzhen Yahui Long Biotechnology Co., Ltd. for inaccurate and incomplete information disclosure regarding its strategic cooperation with Shenzhen Brain Machine Starlink Technology Co., Ltd. [1][2] Group 1: Company Actions - Shenzhen Yahui Long announced a strategic cooperation framework agreement with Brain Machine Starlink, focusing on product development, market promotion, and equity investment [1] - Following media attention, the company issued a supplementary announcement clarifying that Brain Machine Starlink's current research products only involve non-invasive technology and that some products are still in early development or preclinical stages [1][2] Group 2: Market Reaction - The announcement led to a 6.52% increase in the company's stock price, with trading volume rising by 299% compared to the previous trading day [2] Group 3: Regulatory Findings - The company was found to have inconsistent statements regarding the inclusion of invasive technology in its partnership, failing to adequately disclose risks related to cooperation feasibility and uncertainties [2] - The actions of the company violated multiple provisions of the Shanghai Stock Exchange's rules, leading to a regulatory warning for the company and its former board secretary, Wang Mingyang [2]

Group 1 - The core viewpoint of the article is that the Shanghai Stock Exchange issued two regulatory warnings to companies Yahui Long and Yingjixin for inaccuracies and incompleteness in disclosing information related to their "brain-computer interface" business [1] Group 2 - The regulatory warnings were issued on January 7, indicating a proactive approach by the exchange to ensure transparency and accuracy in financial disclosures [1] - The companies involved are listed on the Sci-Tech Innovation Board, highlighting the importance of compliance in emerging technology sectors [1] - The specific nature of the inaccuracies and incompleteness in the disclosures has not been detailed, but it raises concerns about corporate governance and investor trust [1]

北京商报讯（记者 丁宁）在收到上交所问询函后，1月7日晚间，亚辉龙（688575）对问询函内容进行 了回复。 亚辉龙还表示，脑机星链成立时间短，规模较小，推进后续研发需要扩大融资规模，公司短期内不排除 有股权投资、合资等合作安排，但预计投资金额较小，对公司不会有重大影响。 据了解，近期，亚辉龙与深圳脑机星链科技有限公司（以下简称"脑机星链"）签署《战略合作框架协 议》。公告披露，脑机星链成立于2025年9月，注册资本为500万元，主营业务包括脑疾病综合诊断、治 疗与康复。根据框架协议，双方将合作开展市场推广并进行销售收入分成。亚辉龙在问询函回复中表 示，脑机星链在严肃医疗场景下与亚辉龙拟合作的相关产品尚未取得医疗器械注册证，预计最早拿证产 品为迷走神经刺激仪（暂定名，以最终获批为准），能否获证存在不确定性，如果获批，预计公司最早 产生收益的时间不早于2026年11月，且产品上市后的具体销售情况还取决于市场环境等情况，公司相关 市场销售渠道资源转化存在不确定性，本次合作对公司业务无重大影响。 ...